CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells

Wei,Chaogang; Wang,Fengjiao; Liu,Wei; Zhao,Wenlu; Yang,Yi; Li,Kai; Xiao,Li; Shen,Junkang

doi:10.3892/mmr.2017.8257

CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells

Authors:
- Chaogang Wei
- Fengjiao Wang
- Wei Liu
- Wenlu Zhao
- Yi Yang
- Kai Li
- Li Xiao
- Junkang Shen
View Affiliations

Affiliations: Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China, Department of Pharmacy, The Affiliated Children's Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China, Center of Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China
Published online on: December 12, 2017 https://doi.org/10.3892/mmr.2017.8257
Pages: 2901-2906
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Androgens have been recognized to be primary causative agents of prostate cancer. Following binding to the androgen receptor (AR), androgens serve important roles in the carcinogenesis of prostate cancers. ARs serve an important role during all stages of prostate cancer, and inhibiting their function may help to slow prostate cancer growth. In the present study, the AR gene was targeted in androgen‑positive prostate cancer cells using the clustered regularly interspaced short palindromic repeats‑associated protein (CRISPR/Cas) system. A total of three different single‑guide RNAs (sgRNAs) were designed according to the three different target sites in the AR gene. The optimal sgRNA with a specific target effect was effectively screened to cleave the AR gene in androgen‑positive prostate cancer cell lines, and to suppress the growth of androgen‑sensitive prostate cancer in vitro. The AR‑sgRNA‑guided CRISPR/Cas system was able to disrupt the AR at specific sites and inhibit the growth of androgen‑sensitive prostate cancer cells; further studies demonstrated that the decreased cell proliferation was due to cellular apoptosis. The results of the present study suggested that the CRISPR/Cas system may be a useful therapeutic strategy for the treatment of prostate cancer.

View Figures

View References

1	DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI and Jemal A: Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA Cancer J Clin. 66:290–308. 2016. View Article : Google Scholar : PubMed/NCBI
2	Feldman BJ and Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45. 2001. View Article : Google Scholar : PubMed/NCBI
3	Saraon P, Jarvi K and Diamandis EP: Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem. 57:1366–1375. 2011. View Article : Google Scholar : PubMed/NCBI
4	Yuan X and Balk SP: Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol. 27:36–41. 2009. View Article : Google Scholar : PubMed/NCBI
5	Cohen MB and Rokhlin OW: Mechanisms of prostate cancer cell survival after inhibition of AR expression. J Cell Biochem. 106:363–371. 2009. View Article : Google Scholar : PubMed/NCBI
6	Horii T and Hatada I: Genome engineering using the CRISPR/Cas system. World J Med Genet. 4:69–76. 2014. View Article : Google Scholar
7	Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE and Church GM: RNA-guided human genome engineering via Cas9. Science. 339:823–826. 2013. View Article : Google Scholar : PubMed/NCBI
8	Pu J, Frescas D, Zhang B and Feng J: Utilization of TALEN and CRISPR/Cas9 technologies for gene targeting and modification. Exp Biol Med (Maywood). 240:1065–1070. 2015. View Article : Google Scholar : PubMed/NCBI
9	Seeger C and Sohn JA: Targeting hepatitis B virus with CRISPR/Cas9. Mol Ther Nucleic Acids. 3:e2162014. View Article : Google Scholar : PubMed/NCBI
10	Lu XJ, Qi X, Zheng DH and Ji LJ: Modeling cancer processes with CRISPR-Cas9. Trends Biotechnol. 33:317–319. 2015. View Article : Google Scholar : PubMed/NCBI
11	Tang H and Shrager JB: CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer: A personalized molecular surgical therapy. EMBO Mol Med. 8:83–85. 2016. View Article : Google Scholar : PubMed/NCBI
12	Matano M, Date S, Shimokawa M, Takano A, Fujii M, Ohta Y, Watanabe T, Kanai T and Sato T: Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med. 21:256–262. 2015.PubMed/NCBI
13	Wang G, Zhao N, Berkhout B and Das AT: CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape. Mol Ther. 24:522–526. 2016. View Article : Google Scholar : PubMed/NCBI
14	Kawamura N, Nimura K, Nagano H, Yamaguchi S, Nonomura N and Kaneda Y: CRISPR/Cas9-mediated gene knockout of NANOG and NANOGP8 decreases the malignant potential of prostate cancer cells. Oncotarget. 6:22361–22374. 2015. View Article : Google Scholar : PubMed/NCBI
15	Zhang HT, Jun WU, Zhang HF and Zhu QF: Efflux of potassium ion is an important reason of HL-60 cells apoptosis induced by tachyplesin. Acta Pharmacol Sin. 27:1367–1374. 2006. View Article : Google Scholar : PubMed/NCBI
16	Heinlein CA and Chang C: Androgen receptor in prostate cancer. Endocr Rev. 25:276–308. 2004. View Article : Google Scholar : PubMed/NCBI
17	Shore N: Management of early-stage prostate cancer. Am J Manag Care. 20 12 Suppl:S260–S272. 2014.PubMed/NCBI
18	Yu L, Wang X, Zhu D, Ding W, Wang L, Zhang C, Jiang X, Shen H, Liao S, Ma D, et al: Disruption of human papillomavirus 16 E6 gene by clustered regularly interspaced short palindromic repeat/Cas system in human cervical cancer cells. Onco Targets Ther. 8:37–44. 2014.PubMed/NCBI
19	Hu Z, Yu L, Zhu D, Ding W, Wang X, Zhang C, Wang L, Jiang X, Shen H, He D, et al: Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells. Biomed Res Int 2014. 6128232014.
20	Ding Q, Regan SN, Xia Y, Oostrom LA, Cowan CA and Musunuru K: Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell. 12:393–394. 2013. View Article : Google Scholar : PubMed/NCBI
21	Pattanayak V, Guilinger JP and Liu DR: Determining the specificities of TALENs, Cas9, and other genome editing enzymes. Methods Enzymol. 546:47–78. 2014. View Article : Google Scholar : PubMed/NCBI